1. Scrip
  2. >>Focus On Asia

BI India’s First Woman MD May Have To Hit The Ground Running

 
• By Anju Ghangurde

The new leader at Boehringer Ingelheim India has a full plate and significant expectations riding on her to sustain momentum at one of the fastest-growing foreign pharma firms in the country.

Leadership_Green_Cone
Vani Manja To Helm BI India • Source: Shutterstock

Boehringer Ingelheim GmbH has picked experienced senior executive Vani Manja to lead the German multinational’s operations in India, marking the arrival of the company’s first woman country managing director in the largely out-of-pocket market. The executive will also be responsible for BI’s businesses in Bangladesh, Nepal and Sri Lanka.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from India

More from Focus On Asia

NIH Funding Cut Left Less Money On R&D Table, Tariffs Would Add To Woes: Aragen’s CEO

 
• By Vibha Ravi

Funding cuts at the National Institutes of Health, big pharma’s US onshoring moves, GCC partnerships and talks with the Indian government to solve intellectual property challenges are discussed in an interview with Aragen’s CEO, who is also keenly watching the Trump administration’s moves on pharma tariffs

Akeso Explains Ivonescimab Prelim OS Data After Investors’ Negative Reactions

 
• By Dexter Jie Yan

Akeso explains the circumstances behind the release of preliminary overall survival data from a head-to-head Phase III trial with ivonescimab in lung cancer, which some investors viewed as disappointing.

Novotech CEO On Flexible Trial Solutions Amid Tariff, Geopolitical Tensions

 
• By Anju Ghangurde

Novotech's CEO talks about rising interest for trials in regions with “regulatory agility” and “strategic insulation” from geopolitical complexity, especially among emerging and mid-sized biotech sponsors. Operational "reassessment” among some sponsors on exposure to China-based CROs/CRDMOs is another area he discussed.